A phase1 study to evaluate the long toxicology and pharmacological dosing of T20K
Phase of Trial: Phase I
Latest Information Update: 02 Aug 2019
Price : $35 *
At a glance
- Drugs T-20K (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; First in man
- Sponsors Cyxone
- 02 Aug 2019 According to a Cyxone media release, Based on the results from the first dose level achieving the study objective, a higher dose level will not need to be studied.
- 02 Aug 2019 Results presented in the Cyxone media release.
- 12 Jul 2019 According to a Cyxone media release, company will make a further announcement once the final healthy male volunteer in the second cohort has received his last dose.